Business Insider

EMD Serono Receives FDA Approval for New GONAL-f® RFF Redi-ject® Pen

ROCKLAND, Mass., Nov. 13, 2017 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, received approval for a redesigned version of GONAL ...
Monthly Prescribing Reference

GONAL-f RFF Redi-ject Pen Approved

Merck Serono announced that the FDA has approved EMD Serono‘s GONAL-f RFF Redi-ject (recombinant follitropin alfa) injection, a disposable prefilled drug injector pen indicated for the subcutaneous ...
EurekAlert!

Serono receives FDA approval for Gonal-f RFF Pen to treat infertility

Geneva, Switzerland and Rockland, MA, May 27, 2004 -- Serono, Inc., the US affiliate of Serono (virt-x: SEO and NYSE: SRA), announced today that the United States Food and Drug Administration (FDA) ...
Business Wire

EMD Serono Receives FDA Approval for Redesigned Fertility Pen

Gonal-f ® RFF Redi-ject™ (follitropin alfa injection) is indicated for: Induction of ovulation and pregnancy in oligo-anovulatory women in whom the cause of infertility is functional and not due to ...
Monthly Prescribing Reference

FDA Approves New Version of Gonal-f Prefilled Pen

GONAL-f (follitropin alfa injection) is a recombinant human follicle-stimulating hormone (r-hFSH) approved for the treatment female infertility and a rare form of male infertility. Merck announced ...
Business Insider

EMD Serono to Present Real-World Data Analyses at the Annual Pacific Coast Reproductive Society Meeting

ROCKLAND, Mass., March 22, 2017 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced two new real-world data analyses ...